In this study, SFFE treatment reduced glucose levels and reversed dyslipidemia through Nrf2 activation, as evidenced by the reversal of glucose and lipid levels and alterations in hepatic biomarkers. The gene discussed is NFE2L2; the disease is metabolic syndrome.